Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2022-08-13
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-14 (study day 51); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-07 (study day 256); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-25 (study day 305); relationship: N
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-13 (study day 323); relationship: N
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-10 (study day 351); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-01 (study day 464); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.